Friday, 14 November 2014

Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2014 – 2020

Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination. Until recently, amniocentesis, chorionic villus sampling (CVS), maternal serum screening and nuchal translucency (NT) scan were the primary diagnostic and screening methods for chromosomal abnormalities. Advent of non-invasive prenatal test is poised to eliminate disadvantages associated with these methods, such as low rate of accuracy with maternal serum screening and NT scan, and risk of miscarriage with invasive amniocentesis and CVS procedures. This report on non-invasive prenatal testing market studies the current market scenario and future potential for non-invasive prenatal tests globally.

Browse the Non-Invasive Prenatal Testing (NIPT) Market Research Report at

The major non-invasive prenatal tests studied in this report are BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi and VisibiliT. These tests have been extensively analyzed on the basis of factors such as the technology used, cost to patients, reimbursement coverage, accuracy and geographical reach (availability across various countries). The historical market size and forecast for each of these tests in terms of revenue (USD Million) and volume (Number of tests performed) have been given in the report for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall non-invasive prenatal test market and the above tests has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. The report on non-invasive prenatal testing market also provides comparative analysis of major tests for the years 2013 and 2020.

In this research study, the global market for non-invasive prenatal testing has been geographically segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The non-invasive prenatal testing market size and forecast in terms of revenue (USD Million) and volume (Number of Tests Performed) for each region has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The non-invasive prenatal testing market study also includes qualitative analysis of the competitive scenario in these regions such as major collaboration and partnership, entry of new entrants, new product launch and other macro economic factors. The market overview section of the report on non-invasive prenatal testing market comprises qualitative analysis of the overall non-invasive prenatal testing market.

Browse More Medical Devices Related Research Reports at

considering the factors determining the market dynamics such as drivers, restraints and opportunities along with the Porter’s five force analysis and market attractiveness analysis. The market overview chapter also provides information such as major chromosomal aneuploidies (Down syndrome, Edwards syndrome, Patau syndrome and monosomy X, and their incidence rate, technological approach for NIPT and major patents issued to players operating in the market and other companies and academic research institutions.
The report also includes a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global non-invasive prenatal testing market, in terms of percentage share in 2013 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the non-invasive prenatal testing market and accentuate market shares. The report concludes with the profiles of major players in the NIPT market such as Sequenom, Inc., Ariosa Diagnostics, Natera, Inc., Illumina, Inc. (Verinata Health, Inc.), BGI Diagnostics, LifeCodexx AG, Laboratory Corporation of America Holdings (LabCorp) and Berry Genomics. Each company profile comprises information such as company overview, financial overview, product portfolio, business strategies and recent developments.

No comments:

Post a Comment